[Age as a prognostic factor in the treatment effectiveness of patients with ulcerative colitis with help of mesenchymal stromal cells].
The aging process decreases the efficiency of the immune system is to maintain the constancy of the antigenic composition of the body. The process of recognition of own and foreign antigens is becoming less accurate, the intensity of immune responses is reduced. This leads to a characteristic of aging immunopathologic syndromes: an immune deficiency, autoimmunity, increased levels of circulating immune complexes, increased cases of benign monoclonal gammopathy. The weakening of the immune processes affected the clinical features of ulcerative colitis in the elderly. In old age, systemic manifestations of disease are observed in 2 times less, and local--in 2 times more likely than patients aged 20-40 years, with local complications such as profuse bleeding and a decrease in the lumen of the colon, there are 3-4 times more often. Thus, age is a factor that determines the characteristics of the course of ulcerative colitis, the severity of extra-systemic manifestations, prognosis and, consequently, response to therapy. Transplantation of mesenchymal stromal cells in elderly patients with ulcerative colitis is less effective than in patients with young and middle age.